Self-Microemulsifying ALK Inhibitor Composition for Oral Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The compound of formula (I), a new-generation ALK kinase inhibitor, faces challenges with strong hydrophobicity, poor water solubility, and thermal instability, necessitating a formulation that ensures stability, solubility, and effective clinical applicability.
Innovation Solution
A self-microemulsifying pharmaceutical formulation comprising the compound of formula (I) with an oil phase, emulsifier, co-emulsifier, and crystallization inhibitor, forming a microemulsion with particle sizes of about 100 nm under gastrointestinal peristalsis to improve solubility and dissolution rates, enhancing bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the compound of formula (I) is used as a pharmaceutical preparation, then the therapeutic effect is achieved, but the poor water solubility and strong hydrophobicity limit its absorption and bioavailability
Solution Approach 1:
The patent introduces self-microemulsifying excipients (surfactants and co-solvents) as intermediary substances that mediate between the hydrophobic drug compound and the aqueous gastrointestinal environment. These excipients form microemulsion structures that solubilize the hydrophobic compound, enabling its dissolution and absorption in water-based bodily fluids without altering the drug's chemical structure.
Solution Approach 2:
The patent changes the physical state and surface properties of the drug formulation by incorporating excipients that modify the microenvironment around the drug particles. The excipients alter the interfacial tension and create a hydrophilic microenvironment that enables the hydrophobic compound to dissolve and be absorbed, effectively changing the solubility parameters of the formulation.
2Ease of manufacture
If high temperature processing is applied during formulation preparation, then the formulation can be processed and manufactured, but thermal degradation impurities are generated due to the compound's thermal instability
Solution Approach 1:
The patent fundamentally changes the processing temperature parameter from high temperature to room temperature or low temperature conditions. By using self-microemulsifying excipients, the formulation can be prepared through simple mixing and homogenization at low temperatures, completely avoiding thermal degradation while still achieving a homogeneous, bioavailable formulation.
Solution Approach 2:
The patent replaces thermal energy input with mechanical energy input for formulation preparation. Instead of using heat to process the formulation, the patent uses mechanical homogenization and mixing at room temperature to achieve the desired formulation characteristics, thereby eliminating thermal degradation pathways.
3Ease of manufacture
If conventional formulation methods are used, then the preparation process is simple, but the dissolution rate and gastrointestinal mucosa permeability remain poor
Solution Approach 1:
The patent introduces self-microemulsifying excipients as intermediary agents that dramatically enhance the dissolution rate. These excipients form microemulsion structures that increase the surface area and solubility of the drug particles, enabling rapid dissolution in gastrointestinal fluids without requiring complex processing methods.
Solution Approach 2:
The patent creates a composite formulation system combining the hydrophobic drug compound with hydrophilic excipients (surfactants and co-solvents). This composite structure leverages the properties of both hydrophobic and hydrophilic components to achieve rapid dissolution and enhanced permeability while maintaining preparation simplicity.
4Stability of the object's composition
If the compound's strong hydrophobicity is maintained, then the compound's stability is preserved, but the oral bioavailability and patient compliance are compromised
Solution Approach 1:
The patent segments the formulation into distinct functional components: the hydrophobic drug compound maintains its stable core structure, while hydrophilic excipients form a separate but integrated microemulsion phase. This segmentation allows the drug to retain its stability while the excipient phase provides the solubility and bioavailability enhancement.
Solution Approach 2:
The excipients act as intermediary substances that bridge the hydrophobic drug and the aqueous environment. They form a protective microemulsion interface that preserves the drug's hydrophobic stability while providing hydrophilic pathways for dissolution and absorption, thereby maintaining both stability and bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved solubility, dissolution rate, and bioavailability of the ALK kinase inhibitor, maintaining stability and patient compliance through the self-microemulsifying technology.
Implementation Method 1
A self-emulsifying drug delivery system contains no aqueous phase and is mainly composed of a drug, an oil phase, a surfactant, etc., and sometimes contains a cosolvent. It can spontaneously form an oil-in-water dispersion system upon slight stirring when in contact with water.
Implementation Method 2
The nanoemulsion with a particle size of less than 100 nm formed after self-emulsification is also known as a self-emulsifying nano-drug delivery system (SENDDS). After oral administration, SENDDS enters the gastrointestinal fluid and spontaneously forms an O/W nanoemulsion under the peristalsis of the gastrointestinal tract
Implementation Method 3
Self-microemulsifying drug delivery systems (SMEDDS) are oil-based formulations containing surfactants and cosolvents that can rapidly and spontaneously form optically isotropic transparent or translucent microemulsions upon contact with water or gastrointestinal fluids
Implementation Method 4
Lipids in the nanoemulsion decompose under the action of pancreatic enzymes and bile, forming smaller nanoemulsion droplets and bile salt micelles, which further increase drug solubility and promote drug absorption
Implementation Method 5
After oral administration, SENDDS enters the gastrointestinal fluid and spontaneously forms an O/W nanoemulsion under the peristalsis of the gastrointestinal tract
Data Source
Figure 1~2
AI summary
The present invention belongs to the technical field of pharmaceutical formulations, and discloses a self-microemulsifying pharmaceutical formulation composition comprising an ALK kinase inhibitor compound or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The pharmaceutical formulation composition of the present invention exhibits good dissolution, high bioavailability, and stable quality.